

**Corresponding Author:** Nick Black, MD, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Pl, London, United Kingdom ([nick.black@lshtm.ac.uk](mailto:nick.black@lshtm.ac.uk)).

**Conflict of Interest Disclosures:** Dr Black has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

1. Sorita A, Ahmed A, Starr SR, et al. Off-hour presentation and outcomes in patients with acute myocardial infarction: systematic review and meta-analysis. *BMJ*. 2014;348:f7393.

**Notice of Retraction and Replacement: Oostdijk et al. Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial. *JAMA*. 2014;312(14):1429-1437.**

**To the Editor** In the Original Investigation entitled “Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial” published in the October 8, 2014, issue of *JAMA*,<sup>1</sup> we inadvertently reported incorrect secondary outcomes. This was a cluster randomized crossover study comparing the ecological effects of selective digestive decontamination (SDD) vs selective oropharyngeal decontamination (SOD) in 16 intensive care units (ICUs) in the Netherlands.

The errors were due to misclassification of the 2 intervention periods of 1 of the 16 ICUs, discovered in the course of re-checking the code in conjunction with an individual patient data meta-analysis. We have corrected the errors and confirmed that there are no other errors after reviewing our original analysis and findings. The correction, though, has changed some of the secondary end points of the study: the previously reported absence of statistically significant differences in day 28 mortality, ICU mortality, hospital mortality, length of stay, and rate of candidemia are now statistically significant, favoring SDD over SOD. Thus, we have requested that the original article be retracted and replaced.

As a result of the mislabeling of interventions in 1 ICU, the flow diagram and Tables 1, 3, 4, and 5 have changed. For day 28 mortality the correct data are 25.7% during SOD and 23.8% during SDD with a corresponding adjusted odds ratio (OR) of 0.850 (95% CI, 0.774-0.933). For ICU mortality the correct data are 20.0% during SOD and 18.4% during SDD with a corresponding adjusted OR of 0.842 (95% CI, 0.759-0.933). For hospital mortality the correct data are 28.2% during SOD and 26.3% during SDD with a corresponding adjusted OR of 0.857 (95% CI, 0.783-0.938). For length of ICU stay the correct data are median of 6 days (IQR, 4-10 days) during SOD and 6 days (IQR, 4-11 days) during SDD (OR, 1.056 [95% CI, 1.014-1.100]). For candidemia the correct data are 1.0% during SOD and 0.5% during SDD with a corresponding OR of 0.47 (95% CI, 0.30-0.75).

The corrections for these errors indicate that the previously reported absence of statistically significant differences in secondary outcomes has been changed and the article now concludes: “Unit-wide application of SDD and SOD was associated with low levels of antibiotic resistance. Compared with SOD, SDD was associated with lower mortality, reduced length of stay, lower rates of ICU-acquired bacteremia and candidemia, and lower prevalence of rectal carriage of antibiotic-

resistant gram-negative bacteria, but a more pronounced gradual increase in aminoglycoside-resistant gram-negative bacteria.”

We deeply regret this error as well as the confusion caused to *JAMA*, readers, and potentially to physicians. The original article has been corrected. An additional online supplement has been added that includes a version of the original article with the errors highlighted and a version of the replacement article with the corrections highlighted.

Evelien A. N. Oostdijk, MD, PhD  
 Jozef Kesecioglu, MD, PhD  
 Marcus J. Schultz, MD, PhD  
 Caroline E. Visser, MD, PhD  
 Evert de Jonge, MD, PhD  
 Einar H. R. van Essen, MD  
 Alexandra T. Bernards, MD, PhD  
 Ilse Purmer, MD  
 Roland Brimicombe, MD  
 Dennis Bergmans, MD, PhD  
 Frank van Tiel, MD, PhD  
 Frank H. Bosch, MD, PhD  
 Ellen Mascini, MD, PhD  
 Arjanne van Griethuysen, MD, PhD  
 Alexander Bindels, MD, PhD  
 Arjan Jansz, MD  
 Fred (A.) L. van Steveninck, MD, PhD  
 Wil C. van der Zwet, MD, PhD  
 Jan Willem Fijen, MD, PhD  
 Steven Thijsen, MD, PhD  
 Remko de Jong, MD  
 Joke Oudbier, MD  
 Adrienne Raben, MD  
 Eric van der Vorm, MD, PhD  
 Mirelle Koeman, MD, PhD  
 Philip Rothbarth, MD, PhD  
 Annemieke Rijkeboer, MD  
 Paul Gruteke, MD  
 Helga Hart, MD  
 Paul Peerbooms, MD, PhD  
 Lex J. Winsser, MD  
 Anne-Marie W. van Elsacker-Niele, MD, PhD  
 Kees Demmendaal, MD  
 Afke Brandenburg, MD, PhD  
 Anne Marie G. A. de Smet, MD, PhD  
 Marc J. M. Bonten, MD, PhD

**Author Affiliations:** Department of Medical Microbiology, University Medical Center Utrecht, Utrecht (Oostdijk, Bonten); Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht (Oostdijk, Kesecioglu); Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam (Schultz); Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam (Visser); Department of Intensive Care Medicine, Leiden University Medical Center, Leiden (de Jonge, van Essen); Department of Medical Microbiology, Leiden University Medical Center, Leiden (Bernards); Department of Intensive Care, HagaZiekenhuis, The Hague (Purmer, Koeman); Department of Medical Microbiology, HagaZiekenhuis, The Hague (Brimicombe); Department of Intensive Care, Maastricht University Medical Centre+, Maastricht (Bergmans, van der Zwet); Department of Medical Microbiology, Maastricht University Medical Centre+, Maastricht (van Tiel); Department of Intensive Care, Rijnstate

Hospital, Arnhem (Bosch); Laboratory for Medical Microbiology and Immunology, Rijnstate Hospital, Arnhem (Mascini, van Griethuysen); Department of Intensive Care Medicine, Catharina Hospital, Eindhoven (Bindels); Laboratory for Medical Microbiology, Laboratories for Pathology and Medical Microbiology, Catharina Hospital, Eindhoven (Jansz); Department of Intensive Care, Deventer Hospital, Deventer (van Steveninck); Department of Medical Microbiology, Deventer Hospital, Deventer (van der Zwet); Department of Intensive Care, Diaconessenhuis Utrecht, Utrecht (Fijen); Department of Medical Microbiology, Diaconessenhuis Utrecht, Utrecht (Thijssen); Department of Intensive Care, BovenIJ Hospital, Amsterdam (de Jong); Department of Medical Microbiology, Zaans Medical Center, Zaandam (Oudbier); Department of Intensive Care, Groene Hart Hospital, Gouda (Raben); Department of Medical Microbiology, Groene Hart Hospital, Gouda (van der Vorm); Department of Medical Microbiology, Rijnland Hospital, Leiderdorp (Rothbarth); Department of Intensive Care, Flevo Hospital, Almere (Rijkeboer); Department of Medical Microbiology, Flevo Hospital, Almere (Gruteke); Department of Intensive Care, Sint Lucas Andreas Hospital, Amsterdam (Hart); Department of Medical Microbiology, Sint Lucas Andreas Hospital, Amsterdam (Peerbooms); Department of Intensive Care, Antonius Hospital, Sneek (Winsser); Izore, Centre for Infectious Diseases Friesland, Leeuwarden (van Elsacker-Niele, Brandenburg); Nij Smellinghe Hospital, Drachten (Demmendaal); Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen (de Smet); Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands (Bonten).

**Corresponding Author:** Evelien A. N. Oostdijk, MD, PhD, Department of Medical Microbiology, University Medical Center Utrecht, G04.517, PO Box 85500, 3508 GA Utrecht, the Netherlands (e.a.n.oostdijk@umcutrecht.nl).

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kesecioglu reported receiving personal fees from Becton Dickinson. No other authors reported disclosures.

- Oostdijk EA, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. *JAMA*. 2014;312(14):1429-1437.

## CORRECTION

**Errors in Study Group Numbers and Outcome Interpretation:** The Editorial entitled "Rational Use of Antibiotics in the ICU: Balancing Stewardship and Clinical Outcomes"<sup>1</sup> published in the October 8, 2014, issue of *JAMA*, included errors in the numbers of participants randomized and inaccurate sentences regarding the findings of the accompanying trial.<sup>2</sup> The corrections in the Editorial are to accommodate the retraction and replacement of the trial. The numbers of participants, reported in the third paragraph of the Editorial, should be 6040 patients random-

ized to selective digestive tract decontamination (SDD) and 5957 randomized to selective oropharyngeal decontamination (SOD). The last sentence of the third paragraph is revised from reflecting no differences in any outcomes by group to the following: "Compared with SOD, SDD was associated with lower mortality and length of stay." Finally, the penultimate sentence in Editorial about favoring SOD as a more reasonable approach has been removed. This article was corrected online.

- Kollef MH, Micek ST. Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes. *JAMA*. 2014;312(14):1403-1404.
- Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. *JAMA*. 2014;312(14):1429-1437.

## Guidelines for Letters

Letters discussing a recent *JAMA* article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the *JAMA* article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at <http://jamanetwork.com/journals/jama/pages/instructions-for-authors>. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the *JAMA* online submission and review system at <https://manuscripts.jama.com>. For technical assistance, please contact [jama-letters@jamanetwork.org](mailto:jama-letters@jamanetwork.org).

**Section Editor:** Jody W. Zylke, MD, Deputy Editor.